TreatmentTrends

September 2013

TreatmentTrends®: Prostate Cancer Q3 (US) 2013

Introduction:

TreatmentTrends®: Prostate Cancer (US) examines the current trends in the management of prostate cancer in the United States from the per-spective of surveyed urologists and medical oncologists.
This report series provides the opportunity to gain greater understanding of medical practice patterns in prostate cancer by physician specialty and disease setting, physicians’ perceptions of brands and specific product attributes, and to assess the impact of sales and messaging efforts.

Questions Answered in This Report:

  *   Determine the most important issues in the treatment of prostate cancer and how they are being met by the currently available products used by urologists and medical oncologists


  *   Understand current treatment rates and patient shares in different prostate cancer treatment settings (newly diagnosed and recurrent prostate cancer settings). The newly diagnosed settings include localized (low-risk, intermediate-risk, and high-risk), locally advanced, and metastatic prostate cancer. The recurrent settings include biochemically recurrent, non-metastatic castrate-resistant, and multiple lines of metastatic castrate-resistant prostate cancer


  *   Collect information on the promotional messages and activities targeting urologists and medical oncologists


  *   Determine the current attitudes and usage of treatments for patients with bone complications associated with prostate cancer and prostate cancer treatment


  *   Understand the differences between urologists and medical oncologists treatment involvement by prostate cancer setting, and differences in the use of currently available therapies between these specialties, plus their perceptions of unmet needs


  *   Capture interest and familiarity of next generation therapies in development for prostate cancer


  *   Understand the expected usage of emerging therapies and the threats these emerging therapies pose to currently available treatments

Scope:

Sample Methodology:

~50 urologists and ~50 medical oncologists complete a 60-minute online quantitative survey with several open-ended questions for qualitative feedback.

To qualify, respondents must meet the following criteria:

Minimum of 25 prostate cancer patients under management per month

Minimum of 10 metastatic castrate-resistant prostate cancer patients under their personal management per month

Have been in practice a minimum of 2 years and a maximum of 30 years

More than 75% of professional time spent in clinical practice (academic hospital setting allowed 50 percent practice time)

Deliverables:

- Final report in PowerPoint format

- Complete set of frequency tables, summary statistics, and cross tabulations

- Proprietary question slide deck and frequency tables

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Report Dates:

- Wave 1 (Q1): March 2013

- Wave 2 (Q3): September 2013

Physician Research:

- Urologists and Medical Oncologists

Key Drugs Covered:

Zytiga, Xtandi, Xofigo, Jevtana, Provenge, docetaxel, Lupron, Eligard, Zoladex, Casodex, Firmagon

Key Companies Mentioned:

- AbbVie

- Algeta

- Astellas Pharma

- AstraZeneca

- Bayer HealthCare

- Dendreon

- Ferring

- Johnson & Johnson

- Medivation

- Sanofi

Related Reports:

- LaunchTrends®: Xofigo (US)

- LaunchTrends®: Xtandi (US)

- Pharmacor®: Prostate Cancer

- DecisionBase®: Prostate Cancer (Metastatic Castrate Resistant)

- PatientBase®: Prostate Cancer in G7, Brazil, Russia, India, China, Mexi-co, Turkey, and South Korea

- Physician and Payer Forum® (US): Cancer Immunotherapeutics

- Physician and Payer Forum® (US): Payer-Imposed Strategies on Market Access in Non-Small-Cell Lung Cancer and Prostate Cancer

- Physician and Payer Forum® (EU5): The Dynamic Prostate Cancer Land-scape

- Emerging Markets: Prostate Cancer in China

Search Published Reports


Decision Resources Group brands include: